HKSE:9606

Duality Biotherapeutics, Inc. · HKSE · Healthcare · HKD · FY for 2025

Figures on this page computed 2026-11-08 13:27 UTC

Last close

n/aHKD

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-136.5%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
9.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

Growth is the furthest below its sector's middle: 0.13 against 0.46 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.33x

2.34x

0.81x

3.63x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.33x
Its own average over 4 years, 1.40B.
Profit2.34x
Its own average over 4 years, -1.08B.
Free cash flow0.81x
Its own average over 4 years, 223.6M.
Debt3.63x
Its own average over 4 years, 41.3M.
Pricen/a
Its own average over 0 years. Market data

Debt is furthest from its own average, at 3.63 times.

Sales is 1.33 times its own 4-year average; Profit is 2.34 times its own 4-year average; Free cash flow is 0.81 times its own 4-year average; Debt is 3.63 times its own 4-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 4-year average1.33
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Profit against its own 4-year average2.34
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Free cash flow against its own 4-year average0.81
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Debt against its own 4-year average3.63
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
HKD